Poxel (LTS:0RA2) Short Interest


LTS:0RA2 Poxel SA LTS:0RA2
42 GF Score
Price €0.20
GF Value €1.21
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Poxel Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0RA2 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Poxel's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poxel Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poxel's Short Interest distribution charts can be found below:

* The bar in red indicates where Poxel's Short Interest falls into.


LTS:0RA2
42GF Score
Poxel SA LTS:0RA2
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Poxel (LTS:0RA2) Overvalued in 2026?

Based on GuruFocus' analysis, Poxel stock appears to be undervalued. The current stock price of €0.20 is trading 83.2% below its estimated GF Value™ of €1.21. GuruFocus considers Poxel to be Possible Value Trap.

Key valuation signals for LTS:0RA2:

  • Short Interest:
  • GF Value™: €1.21 vs. price of €0.20 (83.2% below fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the LTS:0RA2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poxel Business Description

Other Exchanges POXEL:France7PO:Germany
Address 259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
42GF Score

Get the complete analysis for LTS:0RA2

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€1.21
GF Value